YOUR SEARCH :
Industry: Pharmaceutical
YOUR SEARCH PRODUCED 85 MATCHES. PAGE 1 of 2 Items 1-50 of 85
Ebit and Ethics: Corporate Social Responsibility at Merck, LTD, Thailand
Authors: Kaufmann, L; Tritt, C; Koch, A; Wilrich, M
Product Type: Cases
Source: WHU Otto Beisheim School of Management
Publication Year: 2008
This case provides a comprehensive as well as detailed access to the evolving topic of CSR (corporate social responsibility) for senior bachelor and MBA students. The case study enables them to simulate relevant management decisions within the context of the chemicals and pharmaceuticals industry in the Kingdom of Thailand.
Pfizer Inc's Lipitor: The Celebrity Endorsement Controversy
Authors: Srinivasa, Adapa; Purkayastha, D.
Product Type: Cases
Source: ICMR Center for Management Research
Publication Year: 2008
In 2006, Pfizer, Inc, the world's largest pharmaceutical company, was facing a big challenge in sustaining the sales of its cash cow Lipitor.
GlaxoSmithKline and AIDS Drugs in South Africa (A, B, C, D)
Authors: Yaziji, M.; Lindblom, A.
Product Type: Cases
Source: International Institute for Management Development
Publication Year: 2005
The case describes the interactions among pharmaceutical companies, non-government organisations (NGOs), and governments in the context of the AIDS epidemic in South Africa.
Productivity of Growing Global Energy Demand
Author: McKinsey Global Institute, The
Product Type: Policy and Issue Reports
Source: The McKinsey Global Institute
Publication Year: 2006
To date, the global debate about energy has focused too narrowly on curbing demand. Instead, the best way to meet the challenge of growing global energy demand may be to focus on energy productivity, which reconciles both demand abatement and energy-efficiency.
Market Leader Strategies: Astrazeneca Defending its Turf
Authors: Syeda, I.; Purkayastha, D.
Product Type: Cases
Source: Olalla Domínguez Liste
Publication Year: 2008
This case is about AstraZeneca Plc's strategic defense of its market leadership in the gastrointestinal (GI) drugs market. The strategy proved to be very successful but also came in for strong criticism with many critics contending that the success of Nexium was a triumph of marketing over science.
Eli Lilly Meets Joseph Wesbecker: The Prozac Case
Authors: Anderson, S.; Finley, R
Product Type: Cases
Source: The Case Research Journal
Publication Year: 2005
The case explores the interplay of law, public perception, special interests, and corporate culture in complex litigation.
Pfizer's Intellectual Property Rights Battles in China for Viagra
Authors: Fernando, R; Purkayastha, D.
Product Type: Cases
Source: ICMR Center for Management Research
Publication Year: 2007
This case discusses the numerous intellectual property rights (IPR) litigations for Pfizer Inc in China with regard to Viagra, its blockbuster drug for erectile dysfunction.
Motivating High Performers
Author: Patel, Taran
Product Type: Cases
Source:
Publication Year: 2006
Faculty Rating: 
[1 Faculty Rating] 2726 views
This case study highlights the complexity of managing high performers. It raises the issue of motivation and suggests that a competent manager needs to understand how different motivational tools are required to motivate different kinds of employees.
Eli Lilly: Managing Workplace Diversity and Coping with the Accusations of Racial Discrimination
Authors: Purkayastha, D.; Sharma, N.
Product Type: Cases
Source: ICMR Center for Management Research
Publication Year: 2008
This case aims to help students understand the issues and challenges in promoting and managing workplace diversity.
The Flaxil Label (A, B, C)
Author: Barron, Gregory
Product Type: Cases
Source: Harvard Business School Publishing
Publication Year: 2008
These cases focus on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration .
Biocon Ltd.: Building a Biotech Powerhouse
Authors: Konrad, Alison M.; Nicholls-Nixon, Charlene L.; Chandrasekhar, Ramasastry
Product Type: Cases
Source: Richard Ivey School of Business
Publication Year: 2006
In order for Biocon to grow, the chairman believes that the company must enter the riskier business of drug discovery and development. Without making large investments into new capabilities, the company cannot become a top 10 biotech firm.
Merck Global Health Initiatives (A, B)
Authors: Austin, James E.; Barrett, Diana; Weber, Jeffrey
Product Type: Cases
Source: Harvard Business School
Publication Year: 2001
Focuses on Merck's drug donation program and then raises new issues facing management about what to do about HIV/AIDS in Africa given the company's development of a new therapy. Describes collaboration among many parties including the Gates Foundation, other pharmaceutical companies, and the government of Botswana...
Fighting the Flu: Tamiflu Stockpiling: A Pandemic Preparedness Policy
Authors: Samii, Ramina; Van Wassenhove, Luk
Product Type: Cases
Source: INSEAD
Publication Year: 2008
The case narrates the trigger points that encouraged Roche to increase, by 15-fold, the production capacity of Tamiflu - the antiviral pandemic flu drug recommended by the World Health Organization - since 2004.
Finance Leadership in Novartis Consumer Health Businesses
Authors: Groysberg, Boris; Abrahams, Robin
Product Type: Cases
Source: Harvard Business School Publishing
Publication Year: 2006
Describes and contrasts the roles and challenges of three high-performing finance heads at Novartis Consumer Health businesses in Australia, Japan, and Venezuela. All three faced tremendous pressures in terms of managing time and limited resources, but the particular circumstances of each business made for some specific challenges...
Medmira Laboratories: The US OTC Decision
Authors: Sagebien, Julia; Whellams, M.
Product Type: Cases
Source: Richard Ivey School of Business
Publication Year: 2006
This case explores the decision to pursue at-home HIV testing, which would require the development of new marketing and distribution expertise, as well as attention to new ethical issues, while offering synergies with the company's technology.
betapharm - Be Different or Die
Authors: Habisch, Andrew; Kaiser, Stephen; Kinzl, Petra; Roome, Nigel
Product Type: Cases
Source: European Academy of Business in Society
Publication Year: 2008
After a two-day workshop in 2005 with his top management team, Peter Walter, the founding CEO of betapharm, was wondering what he should do.
Antegren: A Beacon of Hope (A, B, C, D)
Authors: Margolis, Joshua; DeLong, Thomas J.; Heymann, Terry
Product Type: Cases
Source: Harvard Business School
Publication Year: 2007
The CEO of Biogen Idec faces a set of difficult decisions regarding a promising drug for Multiple Sclerosis that is headed for early approval by the FDA.
Procter and Gamble's PuR Water Purifier – The Hunt for a Sustainable Business Model
Authors: Jones Christensen, Lisa; Thomas, Jessica
Product Type: Cases
Source: Kenan-Flagler Business School, UNC-Chapel Hill
Publication Year: 2008
This case presents the range of business models that P&G has explored for the sales and distribution of PuR water purification packets.
Corruption in Germany
Authors: Abdelal, Rawi; Di Tella, Rafael; Schlefer, Jonathan
Product Type: Cases
Source: Harvard Business School
Publication Year: 2008
Why do managers become corrupt? Does corruption ever pay? When do friendly relations cross into bribery? How can CEOs manage and prevent outbreaks of corruption? These and other questions are raised by three short case studies of corruption in Germany.
The Betaseron(R) Decision (A, B)
Author: Buchholtz, A.
Product Type: Cases
Source: The Case Research Journal
Publication Year: 1996
When the FDA gave its approval to Betaseron217 it became the first and only drug found to reduce the attack rate of multiple sclerosis.
The Worldwide Market Withdrawal of the Drug Lipobay/ Baycol By Bayer AG
Authors: Welge, Martin; Berg, Nicola
Product Type: Cases
Source: University of Dortmund
Publication Year: 2003
The teaching objectives are: (1) to illustrate the relevant socio-political actors; (2) to demonstrate which instruments the corporation used to deal with its stakeholders; and (3) to show the impact of cross-national conflict shifting on multinational corporations.
Target Corporation
Authors: Cox, Joshua L.; Berry, Katherine M.
Product Type: Cases
Source: Eugene D. Fanning Center for Business Communication
Publication Year: 2006
Rachel Pourchot entered a Target to fill prescriptions for Ortho Tri-Cyclen, an emergency contraceptive otherwise known as the Plan B pill. The Target pharmacist, she claims, had rudely refused to fill her prescription on moral and religious grounds. PPF launched a letter writing campaign that led over 60,000 supporters to contact Target. For many, the incident cast doubt on the company’s reputation as a non-discriminatory, impartial, and friendly company.
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech
Authors: Higgins, Robert F.; Kazan, Brent; LaMontagne, Sophie
Product Type: Cases
Source: Harvard Business School
Publication Year: 2010
How could the board of Vertex and the ystic Fibrosis Foundation (CFF) fundamentally align the objectives of a for-profit company with those of a non-profit institution?
Socially Responsible Pricing: Lessons from the Pricing of AIDS Drugs in Developing Countries
Authors: Smith, N. Craig; Vachani, Sushil
Product Type: Journal Articles
Source: California Management Review
Publication Year: 2004
Corporate social responsibility has major implications for pricing decisions in some markets. An extreme case is the pricing of life-saving drugs in developing countries...
Biovail Corporation: Revenue Recognition and FOB Sales Accounting
Author: Chapman, Craig J.
Product Type: Cases
Source: Harvard Business School
Publication Year: 2009
Biovail Corporation, a major Canadian pharmaceutical company listed on the New York Stock Exchange, announces that it will miss its quarterly earnings target by $25 to $45 million, blaming $10 to $15 million of the shortfall on a truck accident involving a shipment that left its facility on the last day of the quarter.
Pharmaceuticals and the Developing World
Author: Kremer, Michael
Product Type: Journal Articles
Source: Journal of Economic Perspectives. Vol. 16, Num. 4, Fall 2002
Publication Year: 2002
This article reviews a set of reasons for market failures around the provision of drugs in poor countries, and then discusses various policy prescriptions. It places the corporate experience within a larger public policy context.
Celebrex
Authors: Angelmar, Reinhard; Engsbye, Maiken
Product Type: Cases
Source: INSEAD
Publication Year: 2006
The case describes the development and US launch of Celebrex, the first Cox-2 inhibitor, which is co-promoted by Pfizer and Searle. The launch was phenomenally successful. However, four months after the launch Celebrex is facing three issues: (1) how to address the mix-ups between Celebrex and two other drugs with similar names; (2) how to respond to media reports about deaths and serious side effects associated with Celebrex, which was positioned on safety; and (3) how to prepare for the impending entry of Merck & Co's Vioxx.
Kurt Landgraf and Du Pont Merck Pharmaceutical Co. (A, B)
Authors: Gentile, Mary C.; Grant, Sarah B.
Product Type: Cases
Source: Harvard Business School
Publication Year: 1995
This case encourages student discussion of how organizations can effectively address hiring and promotion concerns of minority groups and women.
Beige Holdings Limited
Authors: Ferris, K.; Muratovic, F.
Product Type: Cases
Source: Thunderbird School of Global Management
Publication Year: 2000
This case examines the reporting practices of a high-flying South African pharmaceutical company, Beige Holdings Ltd.
Methanex: Developing an Integrated Strategy
Authors: Egri, C; Papania, Lisa; Shapiro, Daniel
Product Type: Cases
Source:
Publication Year: 2007
Methanex, the world's largest methanol producer, has grown impressively over the last decade, enabling the company to generously reward its shareholders. Methanex has set itself apart by following a cost leadership strategy as well as by being a champion of responsible care -- the chemical industry's standard in environmental and social responsibility. It is a code of practice relatively unknown outside of North America, especially in many of the developing countries where Methanex operates
Intellectual Property and the Availability of Pharmaceuticals in Poor Countries
Author: Lanjouw, Jean O.
Product Type: Journal Articles
Source: Innovation Policy and the Economy. Vol 3, 2002.
Publication Year: 2002
There continues to be widespread criticism of the extension of patent rights on pharmaceuticals in the developing world as required by World Trade Organization membership. This paper examines arguments in favor and against this strengthening of worldwide patent protection...
Viagra in China: A Prolonged Battle over Intellectual Property Rights
Authors: Li, Yahong; Lu, Jiangyong; Tao, Zhigang; Wei, Shangjin; Chan, Penelope
Product Type: Cases
Source: University of Hong Kong
Publication Year: 2010
Viagra's market entry into China was met with an 11-year battle with local drug companies over Viagra's patent, Chinese trademark and three-dimensional trademark. Pfizer's management is trying to figure out what went wrong in its market entry strategy, how to generate more sales before its patent expires in 2014, and what should be done to better protect the IPR of the drugs it intends to launch in the country.
American Pharmaceutical
Author: Richards, E.
Product Type: Cases
Source: CIBER Case Collection, Indiana University
Publication Year: 2002
Faculty Rating: [1 Faculty Rating] 1254 views
The HIV/AIDS crisis has spurred growing demands for cheaper substitutes for these antiretrovirals, suggesting that more and more countries may permit the sale of cheaper substitutes even before the patents expire. While American Pharmaceutical may legally challenge such activities, it is not clear if the challenges would be legally successful or if they would be politically or commercially prudent.
Compulsory Licensing, Thailand, and Abbott Laboratories
Author: Baron, David P.
Product Type: Cases
Source: Stanford University
Publication Year: 2008
To assess the strategy of Abbott Laboratories regarding Thailand's compulsory licensing and understand the role of non-market factors.
Vioxx: Too Risky for Merck?
Authors: Petersen, Mitchell A.; Singhal, Rashmi
Product Type: Cases
Source: Stanford University
Publication Year: 2007
This case follows Merck's pharmaceutical product Vioxx from initial development to launch and subsequent withdrawal, and considers the decisions made at each stage by the Merck executives involved.
Bristol-Myers Squibb Company – Managing Shareholders' Expectations
Authors: Bryant, Murray J.; Narula, Tapasvi
Product Type: Cases
Source: Richard Ivey School of Business
Publication Year: 2005
A senior accountant at Bristol-Myers Squibb has to assess the appropriateness of revenue recognition as the company has dramatically altered its relationships with its channel customers.
AIDS in South Africa: Patents vs. People
Authors: Tancer, R; Talley, S
Product Type: Cases
Source: Thunderbird School of Global Management
Publication Year: 2000
This case raises the issue of balancing private rights, pharmaceutical patents, and the public interest in controlling the AIDS epidemic in South Africa.
Sharing Knowledge Through Lotus Notes in a Pharmaceuticals Company
Authors: Walsham, Geoff; Hayes, Niall
Product Type: Cases
Source: University of Cambridge
Publication Year: 2001
The case study is concerned with the implementation of groupware technology, with the objective of improving teamwork and knowledge sharing. The case illustrates the importance of the socio-political context in enabling and constraining the effectiveness of the use of an IT system.
Reintroduce Thalidomide? (A, B)
Authors: Diermeier, Daniel; Hermitage, Jason; Thaker, Shail; Heinze, Justin
Product Type: Cases
Source: Harvard Business School
Publication Year: 2006
In the 1960s thalidomide was revealed to cause severe nerve damage and birth defects in newborn infants. Twenty years later it was found to have positive effects when treating patients with leprosy, certain types of cancer and cases of HIV/AIDS.
Medical Papers by Ghostwriters Pushed Therapy
Author: Singer, Natasha
Product Type: Magazine / Newspaper Articles
Source: The New York Times
Publication Year: 2009
Newly unveiled court documents show that ghostwriters paid by a pharmaceutical company played a major role in producing 26 scientific papers backing the use of hormone replacement therapy in women...
Roche and Tamiflu: Doing Business in the Shadow of Pandemic
Authors: Peters, Lars; Gottschalk, Jochen; Feddersen, Timothy
Product Type: Cases
Source: Harvard Business School
Publication Year: 2007
What steps, if any, should Roche take with respect to patent protection and production licensing in the shadow of a potential pandemic?
Top Psychiatrist Didn’t Report Drug Makers’ Pay
Author: Harris, Gardener
Product Type: Magazine / Newspaper Articles
Source: The New York Times
Publication Year: 2008
One of the nation’s most influential psychiatrists earned more than $2.8 million in consulting arrangements with drug makers from 2000 to 2007, failed to report at least $1.2 million of that income to his university and violated federal research rules, according to documents provided to Congressional investigators.
NCI Corporation
Authors: Hilb, Martin; Maier, Victoria
Product Type: Cases
Source: University of St. Gallen
Publication Year: 2005
In just four days, Rene Renz of NCI Corporation transformed the face of the organisational structure in his unit, NCI Europe, while networking with other companies to ensure the continued development and well being of the talent being asked to leave NCI. The case details a high-speed downsizing process, focusing on the unique blend of leadership, thorough preparation, and sense of self-respect and dignity toward others, which enabled Renz to restructure NCI Europe humanely and efficiently.
Vioxx and the Merck Team Effort
Authors: Presley, Holly; Dunning, Rebecca
Product Type: Cases
Source: Kenan Institute for Ethics at Duke University
Publication Year: 2009
The pharmaceutical company Merck continued to market its popular prescription pain reliever, Vioxx, despite mounting concerns over its safety. This case study uses the Merck Vioxx episode to examine the coexistence of competing understandings of mission across organizational subdivisions and the difficulty of regulating drug safety in a market context.
Merck & Company, Inc.
Authors: Gust, Andrew M.; Bartucci, Grant D.
Product Type: Cases
Source: Eugene D. Fanning Center for Business Communication
Publication Year: 2005
An urgent message asked Joan Wainwright, Vice President of Public Affairs at Merck & Company, to call Merck’s General Counsel about news from the Data and Safety Monitoring Board. Wainwright quickly returned the call. What she learned wasn’t good: the latest clinical study on Merck’s blockbuster arthritis drug, Vioxx®, had produced strongly unfavorable results. Wainwright had to decide what Merck should do: leave Vioxx® on the market with a “black box” warning or pull the drug.
The Generics Pharmacy
Author: Kayalar, Jim
Product Type: Cases
Source: Richard Ivey School of Business
Publication Year: 2011
Under the strategic leadership of CEO Benjamin Liuson, The Generics Pharmacy succeeded in formulating a superior value proposal by focusing on the supply and demand side constructs at the bottom of the pyramid and bringing affordable high quality medicines within reach of low income individuals.
Hoechst-Roussel Pharmaceuticals, Inc.: RU 486
Authors: Willem Bol, J.; Rosenthal, David
Product Type: Cases
Source: The Case Research Journal
Publication Year: 1993
Hoechst-Roussel management must decide whether to introduce RU 486 - a contraceptive / abortifacient - to the US market.
The Safety Gap
Author: Harris, Gardener
Product Type: Magazine / Newspaper Articles
Source: The New York Times
Publication Year: 2008
In the belly of an industrial district south of Lyon, France, just past a sulfurous oil refinery and a synthetic vanilla plant, sits a run-down, eight-story factory that makes aspirin, the first pharmaceutical blockbuster.
Indian Pharmaceuticals-- Targeting the Poor Sweetens the Profits Pill
Author:
Product Type: Magazine / Newspaper Articles
Source: Ethical Corporation
Publication Year: 2007
Indian pharma multinational Dr Reddy's chief executive G V Prasad says that patient needs and shareholder value go hand-in-hand “Our vision for the next five years is to ensure that no patient goes without treatment because one is not able to afford it.” A statement from a healthcare charity organisation? No, it is from the head of a pharmaceutical company...
Merck
Authors: Simons, Robert L.; Rosenberg, Kathryn; Kindred, Natalie
Product Type: Cases
Source: Harvard Business School
Publication Year: 2009
This two-class case series allows students to stand in the shoes of CEO Ray Gilmartin during the unfolding stages of a reputational crisis.
YOUR SEARCH PRODUCED 85 MATCHES. PAGE 1 of 2 Items 1-50 of 85